%0 Journal Article
%@ 0268-1161
%A Marcos Rodríguez, Ana Teresa
%A Navarro-Pando, José Manuel
%D 2020
%F uneatlantico:510
%J Human Reproduction
%N 3
%P 827-829
%T Letter: cfDNA testing in recurrent pregnancy loss: a new step in the right way but still raw for the clinical area
%U http://repositorio.uneatlantico.es/id/eprint/510/
%V 36
%X Sir,  In their recently published study, Yaron et al. (2020) expose an interesting strategy based in cfDNA testing (cfDNA-T) which could serve as an alternative to cytogenetic analysis in products of conceptions in recurrent pregnancy loss and could guide further management of this medical topic; however, in our opinion, some important aspects should be considered.  Firstly, Illanes et al. (2007) found that cfDNA concentration in the maternal blood can be detected from Week 4 of gestation but it is only reliable from Week 7. However, others authors’ experience could be different. Clark-Ganheart et al. (2015) recommend cfDNA analysis only after 8 weeks of gestation. Zeevi et al. (2018) reported that aneuploidy screening by cfDNA is not generally accurate before Week 8, leading to a period in pregnancy (namely, Weeks 4 through 8) during which assessment of the genetic status of the embryo is not generally feasible. Galeva et al....